News & Media
Press Releases
September 16, 2026
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation ForumPresentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment
July 7, 2026
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now EnrollingOragenics advances ONP-002 with full Australian trial enrollment and a new FDA engagement milestone.
May 7, 2026
Oragenics Signs Letter of Intent to License CardioDialysis™ TechnologyCompany announces letter of intent expanding its CNS platform portfolio.
April 13, 2026
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002First patient dosed at Mackay Base Hospital in Australia within days of site activation.
March 17, 2026
Oragenics Files Annual Report on Form 10-KOragenics files annual report with the SEC and updates shareholders on clinical and strategic progress.
October 21, 2025
Oragenics Regains Full NYSE American ComplianceCompany confirms full compliance with NYSE American continued listing standards.
Media Coverage
Q2 2026 — TraderTV
Oragenics CEO on TraderTV — ONP-002 Phase 2a LaunchCEO Janet Huffman discusses the Phase 2a trial launch, the concussion treatment market, and Oragenics’ CNS platform strategy.